JATT Acquisition Corp

JATT

KYG507521071

Investment Holding Companies

Market Closed - Nyse Other stock markets 21:00:00 15/05/2024 BST			5-day change	1st Jan Change
5.19 ^USD	+0.58%		+10.19%	-36.40%

2023	JATT Acquisition Corp Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2023	Zura Bio Completes Business Combination With JATT Acquisition	MT

JATT Acquisition Corp Reports Earnings Results for the Full Year Ended December 31, 2022

March 28, 2023 at 10:27 pm

JATT Acquisition Corp reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net income was USD 3.55 million.

Latest news about JATT Acquisition Corp

JATT Acquisition Corp Reports Earnings Results for the Full Year Ended December 31, 2022	28/03/23	CI
Zura Bio Completes Business Combination With JATT Acquisition	21/03/23	MT
Zura Bio Limited completed the acquisition of JATT Acquisition Corp from a group of shareholders in a reverse merger transaction.	19/03/23	CI
JATT Acquisition's Shareholders Approve Merger With Zura Bio	17/03/23	MT
JATT Acquisition Corp announced that it has received $20 million in funding from Ewon Comfortech Co., Ltd.	15/03/23	CI
JATT Acquisition Corp to Transfer to Nasdaq Post Zura Bio Merger; Shares Drop	13/03/23	MT
JATT Acquisition Corp Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
JATT Acquisition Corp Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Jatt Acquisition, Zura Bio to Merge; Zura Will Become a Publicly Listed Entity	17/06/22	MT
Zura Bio Limited signed a letter of intent to acquire JATT Acquisition Corp from a group of shareholders for approximately $160 million in a reverse merger transaction.	16/06/22	CI
JATT Acquisition Corp announced that it expects to receive $20 million in funding from Ewon Comfortech Co., Ltd.	15/06/22	CI
JATT Acquisition Corp Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
JATT Acquisition Corp Reports Earnings Results for the Ten Months Ended December 31, 2021	11/04/22	CI
JATT Acquisition Corp Auditor Raises 'Going Concern' Doubt	10/04/22	CI
Certain Class B Ordinary Shares of JATT Acquisition Corp are subject to a Lock-Up Agreement Ending on 10-JAN-2022.	09/01/22	CI
JATT Acquisition Corp Announces Resignation of Josh Distler as A Director	29/09/21	CI
JATT Acquisition Corp has completed an IPO in the amount of $120 million.	14/07/21	CI
JATT Acquisition Corp has filed an IPO in the amount of $120 million.	15/06/21	CI

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Sector

Investment Holding Companies

More about the company

Income Statement Evolution

More financial data

Sector Shell Companies

	1st Jan change	Capi.
JATT ACQUISITION CORP	-36.40%	70.09M
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+200.06%	7.3B
CHURCHILL CAPITAL CORP VII	+2.10%	982M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+23.30%	799M
ARES ACQUISITION CORPORATION II	+1.74%	661M
E7 GROUP	+5.92%	653M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ADMIRAL ACQUISITION LIMITED	+3.61%	503M
CAPITOL INVESTMENT CORP. VII	-.--%	500M